острый коронарный синдромстенокардияишемическия болезнь сердцаинфаркт миокарда1.Бокарев И.Н., Аксенова М.Б., Хлевчук Т.В. Острый коронарный синдром и его лечение. М.: Издательство УРАО, 2001.2.Ray K, Antman E, Braunwald E. On the rise in vWF after ST elevation myocardial infarction: implication for treatment strategies and clinical outcome. An ENRIRE-TIMI 23 substudy. Eur Heart J 2005; 26: 440–6.3.Hacke W. Stroke: A Disease, that has become treatable. In. Atherothrombosisd. 1998.4.Garcia E et al. Primary Angioplasty vs. Systemic Thrombolysis in Anterior Myocardial Infarction. J AM Coll Card 1999; 33: 605).5.Widimsky P et al. Primary Angioplasty in Patients Transferred from General Community Hospitals to Specialized PTCA Units With or Without Emergency Thrombolysis. Eur Heart J 2000; 21: 823–31.6.Schomig A et al. Stent vs Thrombolysis for occluded coronary artery in patients with AMI.NEJM, 2000; 343: 385–91.7.Aversano T et al. The Atlantic Cardiovascular Patients Outcome Research Team JAMA 2002; 287: 1943–51.8.The European Myocardial Infarction Project Group.Prehospital thrombolysis therapy in patients with suspected acute myocardial infarction. N Eng J Med 1993; 329: 383–9.9.Bjorklund E et al. Pre - hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance - transported real - life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27: 1146–52.10.Бокарев И.Н., Павлов А.В., Янкин В.В. и др. 1997.11.Гнездилова Н.Ю. Лечение больных острым инфарктом миокарда методом "быстрого тромболизиса" и влияние его на отдаленный прогноз. Автореф. дис.. канд. мед. наук. М., 2004.12.Bassan J.P et al. Implementation of reperfusion therapy in acute myocardialtherapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26: 2733–41.13.ESC Guidelines on management of Acute Coronary Syndromes in patients presenting without ST-segment elevation. ESC. 2003.14.Patrono С et al. Plate-Active Drugs: The relationship among dose, effectiveness and side effects. Chest 2001; 119: 39S–63S.15.Yusuf S et al. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Eng Med J 2001; 345: 494–502.16.Kottke-Marchant K et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndrome; the GUSTO-IIb haemostasis substudy. Eur Heart Jorn 2002; 23: 1202–12.17.Ardissino D et al. Coagulation activation and long term outcome in acute coronary syndromes. Blood 2003; 102: 2731–5.18.Eikelboom J.W et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin - treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23: 1771–9.19.Несова Т.Н. Активность комплекса фактора Виллебранда – гликопротеины IIb-IIIa у больных стабильной стенокардией и острым коронарным синдромом. Автореф. дис.. канд. мед. наук. М., 2002.20.Ермолаева О.А. "Белок - предшественник тромба" (растворимый комплекс фибрин - мономера) у больных острым коронарным синдромом. Автореф. дис.. канд. мед. наук. М., 2003.21.Cohen M et al. A comparison of low - molecular - weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy an safety of subcutaneous Enoxiparin in Non-Q-Wave Coronary Events Study Group. N Eng J Med 1997; 337: 447–52.22.Antman E et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q-wave myocardial infarction.TIMI-11B trial. Circulation 1999; 100: 1593–601.23.Long - term low - molecular - mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. FRagmin and fast revascularization during instability in coronary artery disease. Investigators. Lancet 1999; 354: 701–7.24.Unfractionated heparin and low - molecular - weight heparin in acute coronary syndrome without ST-elevation: a meta - analys. Lancet 2000; 355: 1936–42.25.Goodman S et al. Randomized evaluation of the safety and efficacy of enoxiparin versus unfractionated heparin in high - risk patiaetns with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb-IIIa inhibitor epifibatid. Circulation 2003; 107: 238–44.26.Blazing M et al. The A-to-Z Trial: method and rationale for a single trial investigating combined use of low - molecular - weight heparin with the glycoprotein IIb-IIIa inhibitor tirofiban and defining the efficacy of early aggessive simvastatin therapy. Am Heart J 2001; 142: 211–7.27.Andreotti F et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta - analysis of 25 307 patients. Eur Heart J 2006; 27: 519–26.28.Wallentin L. Oral direct thrombin inhibition for anticoagulation in coronary artery disease - focus on the ESTEEM trial. Eur Heart J 2004; 6 (Suppl. B): 9–14. Expert consensus document on b - adrenergic receptor blockers. Eur Heart J 2004; 1341–62.29.Yusuf S et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertension 1993; suppl. 4: 61–73.30.Freemantle N et al. Beta blocade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999; 1730–7.31.Pedersen T. Six - year follow up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Eng J Med 1985; 313: 1055–8.32.Yusuf S et al. Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modification. JAMA 1988; 260: 2259–63.33.Myocardial Iscyemia Reduction with Aggressive Cholesterol Lowering. Schwartz G et oth. JAMA 2001; 285: 1711–8.34.Gurfinkel E et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions(FLUVACS) study. Eur Heart J 2004; 25: 25.